Transforming Outcomes in Hepatocellular Carcinoma: Expert Insights on Applying Evidence to Practice : Episode 6
Other Frontline Immunotherapy-based Combinations in Advanced HCC
Expert oncologists analyze immunotherapy-based combinations in the frontline setting for patients with hepatocellular carcinoma.
EP: 1.Patients With Intermediate Stage HCC Unsuitable for TACE
EP: 2.Patient Profile 1: Advanced HCC Treated with Durvalumab + Tremelimumab
EP: 3.Patients With Intermediate Stage HCC Suitable for TACE
EP: 4.HIMALAYA Study: Durvalumab + Tremelimumab in First-Line Treatment of Advanced HCC
EP: 5.Selecting the Appropriate Frontline Treatment in Advanced HCC
Now Viewing
EP: 6.Other Frontline Immunotherapy-based Combinations in Advanced HCC
EP: 7.Patient Profile 2: Advanced HCC Treated with Lenvatinib
EP: 8.Real-World Evidence for Lenvatinib in Advanced HCC
EP: 9.Treatment Selection in Patients Unsuitable for Atezolizumab + Bevacizumab
EP: 10.Patient Profile 3: Advanced HCC Treatment in Second Line and Beyond
EP: 11.Anti-Angiogenic Systemic Therapies for Advanced HCC in Second Line and Beyond
EP: 12.Systemic Immunotherapies for Advanced HCC in Second Line and Beyond
EP: 13.Treatment Considerations for Advanced HCC in Second Line and Beyond
EP: 14.Management of Child-Pugh B Patients with Advanced HCC
EP: 15.Closing Thoughts on Advanced HCC and Highlights from ASCO GI 2023
Related Videos
Related Content
